Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New Medical Fund Plan to Start in 2009 (Taiwan)

This article was originally published in PharmAsia News

Executive Summary

The Taiwanese government is currently working to set up a fund to encourage growth in Taiwan's healthcare system. In recent years, the growing cost of medical expenses has far surpassed the total healthcare budget. The government hopes the new fund will fix that problem, by supplementing a number of institutions, particularly underfunded rural hospitals. Government officials are expected to continue meeting to finalize a plan for the fund which they expect to submit for approval before the end of the year. (Click here for more

You may also be interested in...



E-cigarette NRT Outlook Heated By Combining With Counseling, Nicotine-Tapering Strategy

Results of three-year study conducted at 17 Canadian sites suggest that e-cigarettes use combined with counseling significantly increased abstinence from smoking cigarettes compared to receiving counseling alone.

Cambridge Nutraceuticals Targets Over 50s With UK Acquisition

Cambridge Nutraceuticals - which develops dietary supplements that have “proven clinical benefits” - has snapped up UK-based Prime Fifty to enhance its offering with products specifically designed for the over 50s.

Henlius Kicks Off Denosumab Trial

Shanghai Henlius Biotech has begun dosing in a Phase I trial for its HLX14 planned biosimilar version of denosumab. Multiple biosimilar developers are vying to take a slice of the market for rivals to Amgen’s Xgeva/Prolia original.

UsernamePublicRestriction

Register

LL1134885

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel